Tecentriq and Avastin improves survival in Phase III cancer trial

Hepatocellular carcinoma is an aggressive cancer estimated to affect more than 50,000 people per year. Credit: humpath.com.



  • Tecentriq plus Avastin improves survival in Phase III liver cancer trial